Penserra Capital Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Penserra Capital Management’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,590	Closed	-$68K	–	620
2017 Q1	$68K	Buy	2,590 +1,110	+75%	+$27.5K	0.01%	317
2016 Q4	$32K	Sell	1,480 -308	-17%	-$5.76K	﹤0.01%	435
2016 Q3	$33K	Buy	1,788 +447	+33%	+$7.75K	﹤0.01%	410
2016 Q2	$22K	Buy	1,341 +111	+9%	+$1.87K	﹤0.01%	468
2016 Q1	$17	Buy	1,230 +410	+50%	+$5.54K	﹤0.01%	467
2015 Q4	$14K	Buy	+820	New	+$16K	﹤0.01%	474

Other funds holding NDRM

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Penserra Capital Management's NDRM Position: Q2 2017 in Review

Penserra Capital Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q2 2017, closing a stake of 2,590 shares — an estimated $68K sold.

Penserra Capital Management first reported a position in NDRM in Q4 2015 and held it in 6 quarters. The position peaked at $68K in Q1 2017. 73 funds tracked by Wall St. Rank hold NDRM as of Q2 2017.

Penserra Capital Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Penserra Capital Management sold 2,590 NeuroDerm Ltd. Ordinary Shares shares in Q2 2017, an estimated $68K.
Penserra Capital Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 6 quarters.
Penserra Capital Management's NeuroDerm Ltd. Ordinary Shares position peaked at $68K in Q1 2017.
73 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q2 2017.

Based on Penserra Capital Management's 13F filing for Q2 2017, filed 7 Aug 2017.